search
Back to results

Study of the Insomnia in Patients With Low Back Pain

Primary Purpose

Primary Insomnia

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Eszopiclone
Placebo
Sponsored by
Duke University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Insomnia focused on measuring Insomnia, Low Back Pain, Hypnotics, Eszopiclone, Pain, Disability

Eligibility Criteria

21 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: • Diagnosis of insomnia based on DSM-IV criteria for insomnia due to a general medical condition (low-back pain); The insomnia must not predate the onset of low-back pain by more than 1 month; Usual nightly TST (Total Sleep Time) < 6.5 hours and/or usual SOL (Sleep Onset Latency) > 30 minutes for the last month prior to screening; ISI (Insomnia Severity Index) > 14 (at least moderate insomnia); Age 21-64 years; Greater than 40 on VAS (Visual Analog Scale) for pain (scale is 0-no pain to 100-worst imaginable pain); Patient Global Impression of Pain of at least 3 (on a 1-5 scale, indicating at least moderate severity); reported Back pain must be greater than reported leg pain, and there must be no signs of spinal nerve root compression; presence of normal motor strength on exam; duration of chronic low back pain of greater than three months; low back pain location must be inferior to T12 and superior to the gluteal fold. Exclusion Criteria: • Significant medical or neurological illness in excess of that which is directly responsible for the chronic low back pain; the presence of an active and significant psychiatric disease with a substantive impact on sleep; meeting DSM-IV criteria for an Axis I disorder within the last three months, or meeting criteria for substance abuse within the last 12 months; current pregnancy; history of hypersensitivity, intolerance, or contraindication to Naproxen/Lansoprazole or Eszopiclone; baseline creatinine of 2.0 or greater; patient taking other medications having significant renal effects (e.g. lithium, ACE inhibitor, angiotensin receptor antagonist, or thiazide/loop diuretics); patients taking other anticoagulants; patients having an allergy to aspirin; history of diagnosed gastric or duodenal ulcer; history of bleeding or clotting diathesis; lifetime history of myocardial infarction or cerebrovascular accident; Elevated PT/PTT/INR (Prothrombin Time, Partial Thromboplastin Time, International Normalized Ratio)at screening; Abnormal kidney function detected in screening labs; history of back related surgery within the past 3 months; history of corticosteroid use in the past 30 days; presence of currently pending litigation or worker's compensation claim related to the chronic low back pain; inability to follow study procedures or complete the study; or the use of any medications that could affect sleep within 5 half-lives of screening; history of back surgery within the past 2 years with the exception of a discectomy; pregnant or lactating females; women of child-bearing potential who will not agree to use approved means of birth control during the trial; history of any surgery within the past one month; history of any major physical trauma within the last 6 months; history of corticosteroid use within the last 90 days; diagnosis of rheumatoid or psoriatic arthritis; history of fibromyalgia; presence of spondyloarthropathy; presence of sciatica; spinal stenosis; presence of any vertebral fractures, spondylolisthesis; or radicular back pain.

Sites / Locations

  • Duke University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

1

2

Arm Description

Placebo

Eszopiclone

Outcomes

Primary Outcome Measures

Mean Subjective Sleep Diary Derived Total Sleep Time (TST)
Nightly total sleep time was averaged from diary entries.

Secondary Outcome Measures

Visual Analog Scale Pain Ratings (VAS)
Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain
Mean Sleep Onset Latency (SOL)
Wake Time After Sleep Onset
Number of Awakenings
Sleep Quality Ratings
Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep
Insomnia Severity Index (ISI)
The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia).
Patient Global Impression of Pain Ratings
Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain)
Roland Morris Low Back Pain Inventory (RMLBPI)
The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 "yes-no" items assessing potential disabilities. Scores range from 0 (no disability) to 24 (severe disability).
Hamilton Depression Rating Scale (HAM-D-24)
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.
Short Form 36 Health Survey Questionnaire (SF-36)
The SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The vitality sub-score assesses energy and fatigue, and ranges from 0 (worst) - 100 (best).
State-Trait Anxiety Inventory (STAI)
Self-rating assessment of anxiety measured by STAI, state anxiety inventory (Scale 40-160, where a lower value shows a larger improvement)

Full Information

First Posted
August 16, 2006
Last Updated
July 2, 2015
Sponsor
Duke University
Collaborators
Sumitomo Pharma America, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00365976
Brief Title
Study of the Insomnia in Patients With Low Back Pain
Official Title
Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain
Study Type
Interventional

2. Study Status

Record Verification Date
June 2015
Overall Recruitment Status
Completed
Study Start Date
August 2006 (undefined)
Primary Completion Date
September 2010 (Actual)
Study Completion Date
September 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University
Collaborators
Sumitomo Pharma America, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to examine whether insomnia due to chronic low back pain can improve with use of eszopiclone.
Detailed Description
There is a great need to develop effective treatments for insomnia in patients with chronic low-back pain. Chronic low-back pain is among the most prevalent of all health complaints, is associated with enormous health-care and productivity costs, reduced quality of life, and limitation of function and is almost universally associated with insomnia (Rives and Douglas, 2004). While it had long been believed that insomnia was a symptom of pain conditions and of little consequence in its' own right, a growing literature suggests that insomnia has important effects on the clinical course of pain syndromes (Smith and Haythornthwaite, 2004). While pain may disrupt sleep, it appears that problems with sleep increase pain and are associated with impairments in daytime function. The emerging point of view is that specific treatment for both pain and insomnia is needed for optimal clinical management (Smith and Haythornthwaite, 2004). Surprisingly, despite the fact that chronic low-back pain is the most common pain condition, the treatment of insomnia in this disease has never been studied. As a result, we propose to carry out the first double-blind placebo-controlled study of the treatment insomnia in patients with chronic low back pain. Comparison(s): We will test the hypothesis that treating the insomnia with eszopiclone 3 mg (ESZ) along with management of pain with naproxen 500 mg bid (NAP) will result in statistically significantly improved sleep compared with placebo. We also propose to test as a secondary hypothesis that treatment with ESZ will lead to significant improvement in pain and daytime function vs. placebo.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Insomnia
Keywords
Insomnia, Low Back Pain, Hypnotics, Eszopiclone, Pain, Disability

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
58 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Placebo Comparator
Arm Description
Placebo
Arm Title
2
Arm Type
Active Comparator
Arm Description
Eszopiclone
Intervention Type
Drug
Intervention Name(s)
Eszopiclone
Other Intervention Name(s)
Lunesta
Intervention Description
Eszopiclone 3 mg po nightly for duration of study blind phase.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo nightly over duration of double blind study phase
Primary Outcome Measure Information:
Title
Mean Subjective Sleep Diary Derived Total Sleep Time (TST)
Description
Nightly total sleep time was averaged from diary entries.
Time Frame
Postnaprosyn baseline, Week 1, week 2, week 4
Secondary Outcome Measure Information:
Title
Visual Analog Scale Pain Ratings (VAS)
Description
Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain
Time Frame
Postnaprosyn baseline, Week 1, Week 2, Week 4
Title
Mean Sleep Onset Latency (SOL)
Time Frame
Postnaprosyn Baseline, Week 1, Week 2 week 4
Title
Wake Time After Sleep Onset
Time Frame
Postnaprosyn Baseline, Week 1, Week 2 week 4
Title
Number of Awakenings
Time Frame
Postnaprosyn Baseline, Week 1, Week 2 week 4
Title
Sleep Quality Ratings
Description
Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep
Time Frame
Postnaprosyn Baseline, Week 1, Week 2 week 4
Title
Insomnia Severity Index (ISI)
Description
The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia).
Time Frame
Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4
Title
Patient Global Impression of Pain Ratings
Description
Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain)
Time Frame
postnaprosyn Baseline, Week 1, Week 2 week 4
Title
Roland Morris Low Back Pain Inventory (RMLBPI)
Description
The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 "yes-no" items assessing potential disabilities. Scores range from 0 (no disability) to 24 (severe disability).
Time Frame
prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
Title
Hamilton Depression Rating Scale (HAM-D-24)
Description
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.
Time Frame
prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
Title
Short Form 36 Health Survey Questionnaire (SF-36)
Description
The SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The vitality sub-score assesses energy and fatigue, and ranges from 0 (worst) - 100 (best).
Time Frame
Baseline, week 1, week 2, week 4
Title
State-Trait Anxiety Inventory (STAI)
Description
Self-rating assessment of anxiety measured by STAI, state anxiety inventory (Scale 40-160, where a lower value shows a larger improvement)
Time Frame
Baseline, week 1, week 2, week 4

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: • Diagnosis of insomnia based on DSM-IV criteria for insomnia due to a general medical condition (low-back pain); The insomnia must not predate the onset of low-back pain by more than 1 month; Usual nightly TST (Total Sleep Time) < 6.5 hours and/or usual SOL (Sleep Onset Latency) > 30 minutes for the last month prior to screening; ISI (Insomnia Severity Index) > 14 (at least moderate insomnia); Age 21-64 years; Greater than 40 on VAS (Visual Analog Scale) for pain (scale is 0-no pain to 100-worst imaginable pain); Patient Global Impression of Pain of at least 3 (on a 1-5 scale, indicating at least moderate severity); reported Back pain must be greater than reported leg pain, and there must be no signs of spinal nerve root compression; presence of normal motor strength on exam; duration of chronic low back pain of greater than three months; low back pain location must be inferior to T12 and superior to the gluteal fold. Exclusion Criteria: • Significant medical or neurological illness in excess of that which is directly responsible for the chronic low back pain; the presence of an active and significant psychiatric disease with a substantive impact on sleep; meeting DSM-IV criteria for an Axis I disorder within the last three months, or meeting criteria for substance abuse within the last 12 months; current pregnancy; history of hypersensitivity, intolerance, or contraindication to Naproxen/Lansoprazole or Eszopiclone; baseline creatinine of 2.0 or greater; patient taking other medications having significant renal effects (e.g. lithium, ACE inhibitor, angiotensin receptor antagonist, or thiazide/loop diuretics); patients taking other anticoagulants; patients having an allergy to aspirin; history of diagnosed gastric or duodenal ulcer; history of bleeding or clotting diathesis; lifetime history of myocardial infarction or cerebrovascular accident; Elevated PT/PTT/INR (Prothrombin Time, Partial Thromboplastin Time, International Normalized Ratio)at screening; Abnormal kidney function detected in screening labs; history of back related surgery within the past 3 months; history of corticosteroid use in the past 30 days; presence of currently pending litigation or worker's compensation claim related to the chronic low back pain; inability to follow study procedures or complete the study; or the use of any medications that could affect sleep within 5 half-lives of screening; history of back surgery within the past 2 years with the exception of a discectomy; pregnant or lactating females; women of child-bearing potential who will not agree to use approved means of birth control during the trial; history of any surgery within the past one month; history of any major physical trauma within the last 6 months; history of corticosteroid use within the last 90 days; diagnosis of rheumatoid or psoriatic arthritis; history of fibromyalgia; presence of spondyloarthropathy; presence of sciatica; spinal stenosis; presence of any vertebral fractures, spondylolisthesis; or radicular back pain.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew D Krystal, MD
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
6462116
Citation
Berry H, Bloom B, Hamilton EB, Swinson DR. Naproxen sodium, diflunisal, and placebo in the treatment of chronic back pain. Ann Rheum Dis. 1982 Apr;41(2):129-32. doi: 10.1136/ard.41.2.129.
Results Reference
background
PubMed Identifier
15153065
Citation
Benca RM, Ancoli-Israel S, Moldofsky H. Special considerations in insomnia diagnosis and management: depressed, elderly, and chronic pain populations. J Clin Psychiatry. 2004;65 Suppl 8:26-35.
Results Reference
background
PubMed Identifier
15476906
Citation
Coats TL, Borenstein DG, Nangia NK, Brown MT. Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial. Clin Ther. 2004 Aug;26(8):1249-60. doi: 10.1016/s0149-2918(04)80081-x.
Results Reference
background
PubMed Identifier
15329041
Citation
Curran MP, Wellington K. Delayed-release lansoprazole plus naproxen. Drugs. 2004;64(17):1915-9; discussion 1920-1. doi: 10.2165/00003495-200464170-00008.
Results Reference
background
PubMed Identifier
15600223
Citation
Edinger JD, Means MK, Stechuchak KM, Olsen MK. A pilot study of inexpensive sleep-assessment devices. Behav Sleep Med. 2004;2(1):41-9. doi: 10.1207/s15402010bsm0201_4.
Results Reference
background
PubMed Identifier
12592542
Citation
Hagg O, Fritzell P, Nordwall A; Swedish Lumbar Spine Study Group. The clinical importance of changes in outcome scores after treatment for chronic low back pain. Eur Spine J. 2003 Feb;12(1):12-20. doi: 10.1007/s00586-002-0464-0. Epub 2002 Oct 24.
Results Reference
background
PubMed Identifier
12698128
Citation
Holm I, Friis A, Storheim K, Brox JI. Measuring self-reported functional status and pain in patients with chronic low back pain by postal questionnaires: a reliability study. Spine (Phila Pa 1976). 2003 Apr 15;28(8):828-33.
Results Reference
background
PubMed Identifier
15140330
Citation
Katz N, Rodgers DB, Krupa D, Reicin A. Onset of pain relief with rofecoxib in chronic low back pain: results of two four-week, randomized, placebo-controlled trials. Curr Med Res Opin. 2004 May;20(5):651-8. doi: 10.1185/030079904125003160.
Results Reference
background
PubMed Identifier
9165992
Citation
Koes BW, Scholten RJ, Mens JM, Bouter LM. Efficacy of non-steroidal anti-inflammatory drugs for low back pain: a systematic review of randomised clinical trials. Ann Rheum Dis. 1997 Apr;56(4):214-23. doi: 10.1136/ard.56.4.214.
Results Reference
background
PubMed Identifier
14655910
Citation
Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, Roth T. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003 Nov 1;26(7):793-9. doi: 10.1093/sleep/26.7.793.
Results Reference
background
PubMed Identifier
14535877
Citation
Lai KC, Lam SK, Chu KM, Hui WM, Kwok KF, Wong BC, Hu HC, Wong WM, Chan OO, Chan CK. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. Aliment Pharmacol Ther. 2003 Oct 15;18(8):829-36. doi: 10.1046/j.1365-2036.2003.01762.x.
Results Reference
background
PubMed Identifier
15564901
Citation
Luo X, Pietrobon R, Curtis LH, Hey LA. Prescription of nonsteroidal anti-inflammatory drugs and muscle relaxants for back pain in the United States. Spine (Phila Pa 1976). 2004 Dec 1;29(23):E531-7. doi: 10.1097/01.brs.0000146453.76528.7c.
Results Reference
background
PubMed Identifier
15949778
Citation
Ostelo RW, de Vet HC. Clinically important outcomes in low back pain. Best Pract Res Clin Rheumatol. 2005 Aug;19(4):593-607. doi: 10.1016/j.berh.2005.03.003.
Results Reference
background
PubMed Identifier
15370723
Citation
Pallay RM, Seger W, Adler JL, Ettlinger RE, Quaidoo EA, Lipetz R, O'Brien K, Mucciola L, Skalky CS, Petruschke RA, Bohidar NR, Geba GP. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol. 2004;33(4):257-66. doi: 10.1080/03009740410005728.
Results Reference
background
PubMed Identifier
15575027
Citation
Rives PA, Douglass AB. Evaluation and treatment of low back pain in family practice. J Am Board Fam Pract. 2004 Nov-Dec;17 Suppl:S23-31. doi: 10.3122/jabfm.17.suppl_1.s23.
Results Reference
background
PubMed Identifier
15033151
Citation
Smith MT, Haythornthwaite JA. How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. Sleep Med Rev. 2004 Apr;8(2):119-32. doi: 10.1016/S1087-0792(03)00044-3.
Results Reference
background
PubMed Identifier
15701215
Citation
Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004 Dec;20(12):1979-91. doi: 10.1185/174234304x15174.
Results Reference
background
PubMed Identifier
24882900
Citation
Goforth HW, Preud'homme XA, Krystal AD. A randomized, double-blind, placebo-controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep. 2014 Jun 1;37(6):1053-60. doi: 10.5665/sleep.3760.
Results Reference
derived

Learn more about this trial

Study of the Insomnia in Patients With Low Back Pain

We'll reach out to this number within 24 hrs